Eli Lilly Amasses $1.5 Billion Orforglipron Stockpile Ahead of April FDA Decision
Eli Lilly has stockpiled $1.5 billion of orforglipron inventory, up from $550 million last year, in preparation for an April FDA approval decision. The drug received a fast-track review voucher that could cut its approval timeline to 1-2 months, enabling near-simultaneous multi-country rollout.
1. Inventory Build-up
Eli Lilly has accumulated $1.5 billion of orforglipron inventory in a regulatory filing, marking a jump from $550 million a year earlier as the company prepares for an FDA decision expected in April.
2. Fast-Track Review and Timeline
The FDA granted orforglipron a fast-track review voucher, potentially reducing the approval process to 1-2 months instead of the typical 10-12 months, accelerating the drug’s time to market.
3. Supply Plans and Coverage Outlook
The company expects sufficient supply for near-simultaneous launches across multiple countries and anticipates planned Medicare coverage expansion for obesity treatments will broaden patient access and drive adoption.